Abivax announces abtect phase 3 trial achieves key enrollment milestone

Abivax announces abtect phase 3 trial achieves key enrollment milestone phase 3 abtect trial evaluating obefazimod in moderately to severely active ulcerative colitis (uc) surpassed the 600-patient enrollment milestone confirming abtect currently on pace to reach full enrollment in early q1 2025 to date, baseline participants baseline characteristics and trial trends in line with observations from phase 2b trial paris, france, august 6, 2024, 8:30 a.m. cest – abivax sa (euronext paris & nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that in july 2024, the 600th participant was enrolled in the phase 3 abtect trial.
ABVX Ratings Summary
ABVX Quant Ranking